Raymond James analyst John Ransom lowered the firm’s price target on Cigna (CI) to $350 from $385 and keeps a Strong Buy rating on the shares. The company reported Q3 results modestly ahead of expectations, and management reaffirmed its 2025 adjusted EPS outlook of “at least $29.60,” though the big reveal was the company is now only expecting modest EPS growth in 2026, the analyst tells investors in a research note. The firm said the company taking a much more proactive and “all at once” approach to recontacting should set the business up for a cleaner base to grow off going forward and helps get out ahead of any regulatory issues.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CI:
- Cigna price target lowered to $310 from $375 at Truist
- Cigna’s Earnings Call: Strong Performance Amid Challenges
- Cigna price target lowered to $355 from $390 at Morgan Stanley
- Cigna price target lowered to $300 from $383 at Barclays
- Cigna’s Strategic Initiatives Poised for Long-Term Growth Despite Short-Term Challenges